Role of FDG-PET in staging and therapy of children with hodgkin lymphoma;Die Bedeutung des FDG-PET für die Stadieneinteilung und Therapie des Hodgkin-Lymphoms im Kindesalter

Klinische Padiatrie

Volumn 223, Issue 6, 2011, Pages 315-319

  Kluge, R ^a   Krholz, D ^b  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Klinik und Poliklinik für Kinder und Jugendmedizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ALGORITHM; ARTICLE; BONE MARROW BIOPSY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; HODGKIN DISEASE; HUMAN; PEDIATRICS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 81855217520     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0031-1287834     Document Type: Article

References (23)

1. Barrington S F, Qian W, Somer E J et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010; 37: 1824-1833
2. Bhatia S, Yasui Y, Robison L L et al. Late Eff ects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Eff ects Study Group. J Clin Oncol 2003; 21: 4386-4394
3. Creutzig U, Herold R, Henze G. Ergebnisse des Kompetenznetzes Pädiatrische Onkologie und Hämatologie-ein Rückblick. Klin Pädiatr 2010; 222: 333-336
4. Dörff el W, Lüders H, Rühl U et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003; 215: 139-145
5. Furth C, Steff en I, Amthauer H et al. Early and Late Therapy Response Assessment With [18 F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial. J Clin Oncol 2009; 27: 4385-4391
6. Furth C, Amthauer H, Hautzel H et al. Evaluation of interim PET response criteria in paediatric Hodgkin.s lymphoma-results for dedicated assessment criteria in a blinded dual-centre read. Anns Oncol 2011; 22: 1198-1203
7. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fl uoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752
8. Gallamini A, Patti C, Viviani S et al. Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Early chemotherapy intensifi cation with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011; 152: 551-560
9. Graf N, Hoppe A, Georgiadi E et al. 'In silico' oncology for clinical decision making in the context of nephroblastoma. Klin Pädiatr 2009; 221: 141-149
10. Horning S J, Juweid M E, Schöder H et al. Interim positron emission tomography scans in diff use large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010; 115: 775-777
11. Hutchings M, Mikhaeel N G, Fields P A et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma . Ann Oncol 2005; 16: 1160-1168
12. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59
13. Juweid M E, Stroobants S, Hoekstra O S et al. Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578
14. Körholz D, Claviez A, Hasenclever D et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Klin Padiatr 2004; 216: 150-156
15. Kostakoglu L, Coleman M, Leonard J P et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018-1027
16. Mauz-Körholz, Hasenclever D, Dörff el W et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable eff ectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28: 3680-3686
17. Meignan M, Gallamini A, Meignan M et al. Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-1260
18. Meignan M, Gallamini A, Haioun C et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010; 51: 2171-2180
19. Meignan M. Interim PET in lymphoma: a step towards standardization . Eur J Nucl Med Mol Imag 2010; 37: 1821-1823
20. Purz S, Mauz-Körholz C, Körholz D et al. FDG-PET for diagnosing bone marrow involvement in children and adolescents with Hodgkin's Lymphoma . J Clin Oncol 2011 Aug 8. [Epub ahead of print]
21. Spaepen K, Stroobants S, Dupont P et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003; 30: 682-688
22. Steidl C, Lee T, Shah S P et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885
23. Wahl R L, Jacene H, Kasamon Y et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 (Suppl 1): 122S-150S